Cargando...
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
The ability to harness a patient’s immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effecti...
Guardado en:
| Publicado en: | Blood |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Hematology
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6032892/ https://ncbi.nlm.nih.gov/pubmed/29728402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-01-785840 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|